title: Angiotensin II type 1 receptor blocker inhibits arterial calcification in a pre-clinical model.
abstract: OBJECTIVE
  Arterial calcification is a common complication of several disorders and is a strong predictor of mortality. The mechanism underlying arterial calcification is not fully understood and as such, no pharmaceutical therapies are currently available which impede its progression. The aim of this study was to investigate the effects of an angiotensin II (AngII) type 1 receptor blocker (ARB) on arterial calcification.
  
  
  RESULTS
  Male New Zealand White rabbits were fed an atherogenic diet to induce atherosclerosis and arterial calcification over a period of 12 weeks, with an ARB administered in the final 4 weeks. Using clinically relevant micro-computed tomography, we found that animals fed the atherogenic diet displayed extensive arterial calcification when compared with control. In contrast, administration of the ARB completely inhibited calcification (2.80 ± 1.17 vs. 0.01 ± 0.01% calcified tissue in cholesterol and ARB-treated, respectively; n = 6 and 5; P < 0.05). Calcified regions were characterized by up-regulation of bone morphogenetic protein 2, osteocalcin, and the AngII type 1 receptor and concomitant down-regulation of α-smooth muscle actin, consistent with a phenotypic switch from vascular to osteoblast-like cells.
  
  
  CONCLUSIONS
  These data provide the first evidence that angiotensin receptor blockade can inhibit arterial calcification by disrupting vascular osteogenesis and suggest that ARBs may be a novel treatment option for patients suffering from vascular calcification.
authors.affiliation: Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, The University of Western Ontario, Medical Sciences Building M426, London, ON, Canada.
authors.forename: Zachary B
authors.initials: ZB
authors.lastname: Armstrong
authors.forename: Derek R
authors.initials: DR
authors.lastname: Boughner
authors.forename: Maria
authors.initials: M
authors.lastname: Drangova
authors.forename: Kem A
authors.initials: KA
authors.lastname: Rogers
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000818:Animals; D050197:Atherosclerosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D055396:Bone Morphogenetic Protein 2 / Q000378:metabolism; D002114:Calcinosis / Q000000981:diagnostic imaging / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D004036:Diet, Atherogenic; D004195:Disease Models, Animal; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D000068557:Olmesartan Medoxomil; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D015675:Osteocalcin / Q000378:metabolism; D010641:Phenotype; D011817:Rabbits; D044140:Receptor, Angiotensin, Type 1 / Q000187:drug effects / Q000378:metabolism; D013777:Tetrazoles / Q000494:pharmacology*; D013997:Time Factors; D055114:X-Ray Microtomography
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D055396:Bone Morphogenetic Protein 2; D007093:Imidazoles; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; D015675:Osteocalcin; D000068557:Olmesartan Medoxomil